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lation over 80 years old, and there is no current treatment
or cure. FAP can cause debilitation from as early as
25 years old, and the only possible treatment is liver
transplantation for compatible individuals [4, 5]. To date,
over 70 disease-related point mutations of TTR have
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characterized by X-ray analysis show no significant ef-2 Oxford Centre for Molecular Sciences
University of Oxford fect on the tertiary structure of the protein [6] but appear
to destabilize the tetramer, a prerequisite suggested forSouth Parks Road
Oxford OX1 3QH amyloid formation [7]. This is supported by the observa-
tion that fibril formation is increased at pH 4.4, where3 Department of Biochemistry
School of Medical Sciences dissociation of the tetramer occurs readily [8].
TTR is found in plasma and cerebrospinal fluid (CSF)University of Bristol
Bristol BS8 1T as a biologically active homotetramer having 2,2,2 mo-
lecular symmetry (Figure 1). The C2 symmetric hormoneUK
4 The Skaggs Institute for Chemical Biology binding sites that run through the center of the structure
can carry two thyroxine molecules simultaneously. InThe Scripps Research Institute
10550 North Torrey Pines Road addition, up to two molecules of vitamin A (retinol) are
transported through complexation with retinol bindingBCC-506
La Jolla, California 92037 protein (RBP). The TTR:RBP:retinol complex is the only
transport system for vitamin A. In CSF, TTR is the main
thyroxine transport system, and under normal condi-
tions, 75% of the protein exists as this complex. TTR inSummary
plasma acts as a backup system to thyroxine binding
globulin for thyroxine transport, and, consequently, onlyTetrameric transthyretin is involved in transport of thy-
10% of the hormone binding channels are occupied.roxine and, through its interactions with retinol binding
That there is no evidence of fibril deposition in brainprotein, vitamin A. Dissociation of these structures is
tissue suggests that thyroxine binding may prevent dis-widely accepted as the first step in the formation of
sociation of TTR in vivo. This, in addition to the fact thattransthyretin amyloid fibrils. Using a mass spectro-
the ligand binding channels are unoccupied in plasma,metric approach, we have examined a series of 18
suggests that binding and stabilization by thyroxine ana-ligands proposed as inhibitors of this process. The
logs is a possible therapy for TTR amyloidoses [9, 10].ligands were evaluated for their ability to bind to and
The hormonal activity of thyroxine make its applicationstabilize the tetrameric structure, their cooperativity
as a therapy undesirable, but recently, small moleculesin binding, and their ability to compete with the natural
that complement the known binding site of TTR haveligand thyroxine. The observation of a novel ten-com-
been examined. Of those found to inhibit fibril formation,ponent complex containing six protein subunits, two
several contained the bisarylamine scaffold and in-vitamin molecules, and two synthetic ligands allows
cluded the nonsteroidal anti-inflammatory drug flufena-us to conclude that ligand binding does not inhibit
mic acid [11, 12]. X-ray analysis of this ligand withinassociation of transthyretin with holo retinol binding
the TTR tetramer provided a starting point for rationalprotein.
structure-based drug design of fibril inhibitors. Ligands
based on the N-phenyl phenoxazine scaffold were de-
Introduction signed to occupy a greater proportion of the thyroxine
binding channel and have been shown to be effective
Transthyretin (TTR) is one of 20 or so human proteins by an in vitro turbidity assay [13].
that form amyloid fibrils associated with diseases such The use of mass spectrometry to investigate protein-
as Alzheimer’s and the transmissible spongiform en- protein [14, 15] and protein-ligand [16, 17] interactions
cephalopathies [1, 2]. Under normal conditions, TTR has been reported extensively, and recent studies have
transports the hormone thyroxine and vitamin A (retinol) also described its use to elucidate cooperativity in multi-
in humans, but misfolding of wild-type and single point subunit systems [18, 19]. We have shown that, under
mutations lead to senile systemic amyloidosis (SSA) and the appropriate conditions, solutions of apo TTR and
familial amyloid polyneuropathy (FAP), respectively. apo TTR:RBP:retinol give rise to mass spectra con-
SSA is caused by a build up of TTR amyloid in heart taining peaks assigned to tetrameric and hexameric
tissue, leading to arterial fibrillation, congestive heart
failure, and death [3]. SSA affects 20% of the male popu-
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Figure 1. Structure of Ligand-Bound Trans-
thyretin
(A) TTR tetramer with individual subunits in
red, blue, yellow, and green. Two subunits
constitute one thyroxine binding site,
allowing two hormones to bind per tetramer
(blue space fill). Relevant point mutations are
indicated on upper left monomer.
(B) The natural hormone thyroxine (ball and
stick) in complex with TTR. TTR colors as in
(A), but residues 16–26 of the blue and green
subunits have been removed for viewing. Im-
portant residues in ligand binding are indi-
cated.
(PDB code 2ROX, Swiss-PDB viewer 3.6b3.
Rasterised with POV-Ray 3.1g).
complexes, respectively [20, 21]. In these investigations, Here we examine 18 small molecules proposed as
inhibitors for their ability to stabilize the tetrameric struc-solutions of the complexes were analyzed by electro-
spray ionization and subjected to increasingly harsh de- tures of human wild-type and variant TTR against in-
creasingly harsh desolvation conditions. The ligandssolvation conditions to effect their dissociation. The
mechanism of dissociation of complexes in the mass were examined without prior knowledge of their struc-
ture under amyloidogenic solution conditions to firstspectrometer is a topic of considerable current interest.
It has been established, through detailed analysis of the identify binding to TTR at the molecular level and then
to assess their efficacy in stabilizing the tetramer. Arates of dissociation of gas-phase noncovalent complex
ions, that some structural features of solution phase subset of potential ligands was found to compete effec-
tively for TTR hormone binding sites in the presence ofcomplexes are retained, even following relatively long
time intervals [22]. Moreover, small protein:ligand com- the natural hormone thyroxine. Negative cooperativity
was established for the majority of ligands that bind toplexes have been shown to be sensitive to the nature
of the interactions [23]. For example, where the major wild-type and variant TTR, although noncooperative and
cooperative binding was established for four ligands. Adriving force for ligand binding is hydrophobic, such
complexes often dissociate, while ionic interactions are further criterion for evaluation of potential ligands was to
maintain transport of retinol via interactions with humangenerally enhanced in the gas phase of the mass spec-
trometer. A positive correlation between the polar sur- RBP. We have established that thyroxine-bound wild-
type TTR and variants are competent to bind holo retinolface area of the ligand and the strength of the interaction
in the gas phase was demonstrated for an individual binding protein. Synthetic ligands were also assessed
for perturbation of the RBP:retinol binding site, and theprotein in complex with a number of ligands with diverse
properties [24]. Recently, however, this correlation with results demonstrated that complex formation was not
impaired.the nature of the interaction has been shown to be less
critical for small ligands binding to large proteins. In a
study of the interactions between a 56 kDa protein and
Results and Discussiontripeptide ligands, a greater stability of the complex with
hydrophobic side chains in the peptide was observed
Screening for Ligand Binding to Wild-Type TTRthan for those containing ionic moieties, in line with
Figure 2 shows the mass spectra recorded for a 20 Msolution phase measurements for this system [25]. This
solution of wild-type TTR at pH 4.4 in the presence ofdifference, between the results obtained for small pro-
a 3-fold excess of an N-phenyl phenoxazine (ligand 2 intein complexes (20–30 kDa) and larger ones (50–60 kDa),
Figure 3). Under very mild desolvation conditions (coneis explained at least in part since the size of the protein
voltage 80 V), essentially four charge states are ob-is sufficient to bury ligand such that depletion of solvent
served (10 to13) that give rise to a molecular weightduring the desolvation process does not have a signifi-
consistent with binding of two molecules of ligand tocant effect. Thus large proteins in complex with small
the TTR tetramer. No peaks were observed to indicatemolecule ligands, often present within binding pockets
binding of less or more than two ligands. The peaksor channels, appear to be less sensitive to desolvation.
assigned to these oligomeric structures are broaderThis should also be the case for the 55 kDa tetramer of
than those observed for monomeric proteins, a commonTTR where ligand binding takes place within the hor-
feature attributed to binding of solvent molecules in themone binding channel. Previous results have shown that
interfacial regions of the protein complex [20]. In Figurefor wild-type and variant TTR, conditions can be found
2, the small series at higher m/z (D) corresponds to anwhereby a strong correlation exists between the solution
octamer of TTR and indicates some weak dimerizationequilibrium and the proportion of tetramer within the
of tetramer.mass spectrum [20]. It is interesting to note that while
As the desolvation energy was increased (cone volt-this correlation is evident when the molecular ions are
age 140 V), the series assigned to the octamer was foundexamined shortly after their formation, presumably when
to decrease in intensity, and a fine structure becamethey are still essentially hydrated, ions sampled much
evident within the peaks assigned to the tetramer. Thelater after their formation are less sensitive to the effects
of the mutation (our unpublished data). three major components that are visible in the spectrum
Screening Inhibitors by Mass Spectrometry
853
Figure 2. Nanoflow Electrospray Mass Spectra of holo TTR
Spectra of wild-type TTR in complex with ligand 2. Under the gentlest desolvation conditions, one charge state series is observed corresponding
to TTR tetramer  two ligands (T2), with a small signal indicating octomer (D). As the desolvation energy is increased within the mass
spectrometer, this series dissociates from T2 to tetramer  one ligand (T1) and apo tetramer (T). Under harsher desolvation conditions, the
major species corresponds to apo tetramer, which dissociates to apo trimer and monomeric TTR. * indicates the microheterogeneity of the
TTR resulting from an N-terminal MG truncation. Inset, dissociation of ligand 10 resulted in spectra dominated by apo and T2 tetramer peaks,
with only a low intensity signal evident for T1.
are assigned by their respective masses to apo TTR (T) For example the spectra of wild-type TTR with ligands
16, 8, and 13 were obtained under increasingly harshand TTR with one (T1) and two (T2) bound ligands (Figure
3). Further increases in desolvation energy remove both desolvation conditions in order to observe a similar pro-
file of three peaks corresponding to binding of one andligands, and the mass of tetrameric species measured
at the onset of the peak now corresponds closely to two ligands to TTR (Figure 4). For ligand 16, the condi-
tions are such that extensive binding of solvent mole-that calculated for the mass of four monomers. In addi-
tion, the appearance of peaks, assigned to apo trimer cules is evident in the broad peak widths and increased
measured mass of the ligand-bound complex (Figure 3).and apo monomer, confirms dissociation of the tetra-
mer. At the highest desolvation energy (200 V), tetra- By contrast, spectra recorded for ligand 8 gave rise to
well-resolved peaks as ligand dissociation occurs undermeric and trimeric TTR are present in approximately
equal intensities, while monomeric TTR is the dominant conditions where the majority of solvent molecules have
been removed. For TTR:13 the complex is more stable,form. The fact that the tetramer remains intact after the
ligands have dissociated indicates that for wild-type and under the conditions where ligands remain bound,
virtually all solvent molecules can be removed. This isTTR under these conditions, subunit interactions are
significantly stronger than those between protein and reflected in the fact that the measured mass is much
closer to the theoretical mass for this complex. Theligand. The sequential loss of ligand under increasingly
harsh desolvation conditions to yield the apo TTR was increased resolution of the peaks also reveals the micro-
heterogeneity of the TTR tetramer resulting from an N-ter-found to be the case for all ligands examined with the
wild-type protein, with the exception of one. The com- minal MG truncation. These results highlight the ability
of our approach to manipulate the conditions within theplex formed with ligand 10 was observed to dissociate
directly from T2 to apo TTR (Figure 2, inset), suggesting mass spectrometer to enable us to evaluate a range
of ligands from weakly associated through to tightlya more cooperative mode of dissociation. Interestingly,
even under the gentlest desolvation conditions, we were binding.
Spectra recorded for wild-type TTR in the presenceunable to observe any complex formation with ligands
17 or 18. of ligands 9, 12, and 2, under identical MS and solution
conditions, exhibit very different properties. Ligands 9Screening of the remaining ligands was carried out to
assess their binding to wild-type TTR. It was found that and 12 are fully and partially dissociated, respectively,
while both molecules of ligand 2 are tightly bound tovery different desolvation conditions were necessary to
observe each ligand in complex with the TTR tetramer. wild-type TTR. These results provide a rank order for
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Figure 3. Structure of the Eighteen Synthetic Ligands Used in This Investigation
The molecular masses represent those measured for one and two ligands bound to the TTR tetramer. The measured mass of apo TTR is
55602  3 Da and the calculated mass is 55568 Da.  refers to the standard deviation from the average MW calculated for all charge states.
R  H unless otherwise stated. Molecular mass is in Da. MPSA (molecular polar surface area) in A˚2 [40].
ligand binding to the tetramer of 2 12 9. The sensitiv- tein. It is interesting to note that the mass spectra re-
corded for apo L55P TTR displayed an extended chargeity of this approach is further demonstrated by compar-
ing three derivatives of the N-phenyl phenoxazine struc- state distribution from 9 to 13, while under identical
solution and instrument conditions, that observed forture. From spectra recorded under identical MS
conditions, it can be seen that the stability of the com- the wild-type protein (at pH 7.0) was more compact,
at 11 to 13 (data not shown). The appearance ofplex can be readily distinguished and used to predict a
rank order of the binding strength for these closely re- additional charge states in mass spectra is indicative
of an increased number of conformations [26]. This ex-lated structures of 1  2  3.
tended charge state distribution was also observed in
the presence of ligands (Figure 5). For the 9 chargeScreening for Ligand Binding to Variant TTR
The binding of synthetic ligands to variant TTR was state, both ligands are retained, while within the same
spectrum, the13 charge state shows that the apo forminvestigated in a similar manner as that described for
the wild-type protein. The amyloidogenic nature of V30M of the protein is the major species. This illustrates the
effect of additional charging of the protein tetramer,and L55P renders them prone to aggregation at pH 4.4,
and they were therefore analyzed at pH 7.0. In addition, which increases ligand dissociation, presumably as a
result of partial unfolding.their inherent instability required the use of increased
pressures within the mass spectrometer to maintain the In spite of the broadening of the peaks, enhanced
instability of the tetramer and increased tendency fornoncovalent tetramer. As a consequence of this, the
peaks corresponding to the tetramer in the mass spectra ligand dissociation, it was possible to observe ligand
binding to variant TTR. Individual ligands were addedare broader than those observed for the wild-type pro-
Screening Inhibitors by Mass Spectrometry
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Figure 4. Effects of Ligand Binding to Wild-
Type TTR
(A) Under very different desolvation condi-
tions it is possible to maintain TTR complexes
with ligands of different binding properties
(16, 8, and 13 at cone voltages of 80, 100,
and 120 V, respectively).
(B) Comparison of the spectra for three li-
gands with very different binding properties
under identical MS conditions (100 V) indi-
cates their differing extent of dissociation.
(C) Differences can be observed for the tight-
est binding ligands under identical MS condi-
tions (160 V).
to solutions of each variant in 3-fold excess. Ligands and 14. These results confirm that the effect of the V30M
and L55P mutations does not prevent ligand binding.17 and 18 displayed no additional peaks, indicating that
they do not bind to the variant proteins under these Inhibitor binding was found to be broadly similar for
both variants, with notable differences apparent whensolutions conditions, in line with similar observations for
the wild-type protein. For the L55P variant, ligands 1, 2, compared with the wild-type for binding of ligands 5
and 6.and 3 fully saturate both binding sites, while 4 and 7
display only weak binding when examined under identi-
cal MS conditions. Similarly for V30M, only weak binding Inhibitor Binding versus Tetramer Stability
During dissociation of variant TTR, in the presence orwas observed for ligands 4, 10, and 16, while 1, 2, and
3 also saturated both binding sites. Interestingly 5 and absence of ligand, a higher proportion of trimer was
observed than for wild-type (Figure 5, inset). Figure 5B6, which bound readily to wild-type TTR, displayed no
significant binding to either V30M or L55P under the shows the high m/z region of the mass spectra recorded
during the dissociation of holo tetrameric complexessolution conditions used in this investigation. Binding
in both sites was, however, observed for ligands 8, 10, formed between ligand 2 and either wild-type, V30M, or
Figure 5. Dissociation of holo TTR
(A) Mass spectrum recorded for the dissociation of L55P:22 at a cone voltage of 120 V. The appearance of an extended charge state distribution
for this variant compared with that observed for the wild-type TTR is indicative of a less compact, more unfolded structure. Inset, full mass
spectrum of L55P22 showing the increased proportion of trimer during dissociation when compared to wild-type TTR (180 V).
(B) Formation of trimer during dissociation of wild-type (i) at 200 V, V30M (ii) at 200 V, and L55P at 180V (iii) in the presence of ligand 2. Ligand
binding to the trimer is apparent for both variants. The percentages of trimeric species as a function of the total signal intensity are 24%,
36%, and 56% for wild-type, V30M, and L55P, respectively.
Structure
856
L55P TTR from pH 7.0 solution conditions. The spectra acid derivatives, gave rise to closely similar effects in
stabilizing the tetramer. For the phenoxazine ligands,focus on the trimeric dissociation products of these
three complexes, which occur simultaneously with the the wild-type TTR tetramer structure, which is amyloido-
genic at pH 4.4, was stabilized to an extent comparableappearance of peaks assigned to monomeric TTR. In
the presence of ligand 2, wild-type TTR from solution to that observed from solution at pH 7.0. It is interesting
to note that in general there was a strong correlationat pH 7.0 dissociates to give apo monomeric and apo
trimeric products, in line with the results shown pre- between the stability of ligand binding to TTR and the
stability of the tetramer structure. Figure 6 shows theviously for dissociation of the wild-type TTR:2 complex
(Figure 2). In the case of V30M, peaks assigned to apo ligands ranked according to the proportion of tetramer
dissociation observed at cone voltage 180V, illustratingtrimer and trimer with one ligand are present in approxi-
mately equal proportions, with a smaller peak corre- clearly the correlation between tetramer stabilization
and strength of ligand binding. It is particularly interest-sponding to trimer with two ligands. For L55P, the disso-
ciation of the ligand-bound tetramer leads to formation ing that only the natural ligand thyroxine and ligand 10
(identified as having an unusual mechanism of coopera-of trimer with one and two ligands as the major dissocia-
tion products. The presence of ligand in the trimer com- tive dissociation) display unusually enhanced binding,
not predicted from their position in the series. The cis-plex suggests that for these variants, particularly L55P,
the first component to be expelled as the desolvation and trans-stilbene derivatives, ligands 15 and 16, bound
loosely to TTR but did not stabilize the tetramer. Theenergy is increased is not ligand, but monomer. This
dissociation pathway, where monomeric subunits are N-phenyl phenoxazines display the most effective bind-
ing as well as enhanced tetramer stability. Notable ex-expelled before ligand, was only observed for thyroxine
and ligands 1, 2, and 3 in complex with variant TTR. ceptions to this correlation are ligand 10 and thyroxine.
Both formed relatively tightly bound complexes withNo ligand was observed bound to trimeric TTR during
dissociation of the wild-type. Although the dissociation TTR (intermediate between those of ligands 1–3 and
4–7), but their effect on subunit interactions was lesspathways could not be recorded under identical mass
spectrometry conditions due to the inherent differences pronounced. By contrast, ligands 4–7, although effective
in stabilizing the tetramer, were more readily dissociatedin the stabilities of the complexes, we can conclude
from these observations that in contrast to wild-type from the complex than 1–3, 10, and thyroxine. It is inter-
esting to note that while there is range of values re-TTR, binding of protein subunits is destabilized relative
to ligand interactions in the variant protein:ligand com- corded for ligand dissociation from the tetramer (from
3% to 100%), the differences measured for subunit inter-plexes.
An important criterion in the selection of ligands is to actions are less marked (from 35% to 65%) for the major-
ity of ligands. The greater disparity for ligand binding isdistinguish between their stability within the holo com-
plex and their effect on the strength of subunit interac- interpreted in terms of the diverse structural properties
of the ligands having a discernible effect on the stabilitytions. In this study we have used two different ap-
proaches to rank ligands. The first, described above, of the TTR ligand complex. The effects on subunit inter-
actions, however, are less pronounced, presumablyassesses the relative stability of each inhibitor-bound
complex by comparing the conditions required within since the changes to the subunit interactions that occur
in the holo complexes are closely similar irrespective ofthe mass spectrometer to maintain protein-ligand inter-
actions. The second approach, designed to measure the bound ligand.
In the light of these results, a representative selectionthe efficacy of individual ligands, quantifies the effects
of ligand binding on the strength of subunit interactions of ligands (1–8, 10, and 16) was examined for their ability
to stabilize tetrameric structures of V30M and L55P atin the TTR tetramer. For this latter approach, the propor-
tion of the dissociation products (monomeric and tri- pH 7.0. The results were broadly similar to those ob-
tained for wild-type in that all ligands conferred addi-meric TTR) relative to the tetramer was computed in the
presence of each small molecule inhibitor. The results tional stability compared with solutions in the absence
of ligand, but some notable exceptions were discovered.of both sets of investigations are presented in Figure 6.
Control experiments, examined under identical condi- Ligand 5, which bound to and stabilized wild-type TTR,
was found to have very little effect on the stability oftions, involved the analysis of wild-type TTR at pH 4.4
and pH 7.0 in the absence of ligand in solution as well either mutant under these solution conditions. This cor-
as at pH 4.4 in the presence of thyroxine. It is important relates with our earlier findings where little binding to
to note that under these conditions, spectra recorded variant TTR could be identified for this ligand. Ligand
for solutions in the absence of ligand at pH 4.4 show that 16, which was observed to bind to wild-type TTR but
TTR is fully dissociated. By contrast, for TTR analyzed at have no discernable stabilizing effect, was found to in-
neutral pH in the absence of ligand or in the presence crease the stability of the mutant structure slightly. The
of thyroxine, two conformations not prone to fibril forma- most promising results were from ligands 1–3, in terms
tion, the tetrameric species remain essentially intact. It of both their strength of binding to variant TTR and
is noteworthy that even at pH 4.4, it was not possible stabilization of the tetramer.
to dissociate fully the wild-type tetramer in the presence
of a number of the ligands that bind to TTR. This demon-
Competition for Ligand Binding Sitesstrates the increased stability afforded to the tetramer
To investigate the ability of synthetic ligands to competeas a result of ligand binding.
with thyroxine in solution we examined wild-type orIn general, ligands with the same basic architecture,
for example the N-phenyl phenoxazines and flufenamic L55P TTR with equimolar concentrations of thyroxine
Screening Inhibitors by Mass Spectrometry
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Figure 6. Stability of holo TTR and Competition for Ligand Binding Sites
(A) Stability of the holo TTR tetramer as a function of desolvation energy for each TTR-ligand complex. The relative binding strength of ligand
to wild-type TTR was determined from the proportion of apo and holo TTR at 100 V (red diamond). The strength of subunit interactions was
measured at a cone voltage of 140, 160, and 180, designated by increased color intensity. Yellow indicates ligands for which no binding was
observed, and orange indicates ligand which was observed to bind to, but not stabilize, the TTR tetramer. Ligands that effectively stabilized
the TTR tetramer are colored blue, with the most tightly binding shown in purple. The strength of subunit interactions in the ligand-bound
complexes was compared with solutions of TTR in the absence of ligand at pH 4.4 and 7.0 (green).
(B) Competition of synthetic versus natural ligand in wild-type TTR. The mass spectra at 50% intensity of TTR in the presence of ligand 3
and thyroxine (i) indicates that only TTR:32 complexes are formed. When examined in the presence of thyroxine with ligand 2, complexes
from both synthetic and natural ligand are observed (ii). For ligand 10 (iii), only binding of thyroxine was observed. T(n) indicates TTR tetramer
with n-bound synthetic ligands. Binding of n molecules of thyroxine is designated by Ty(n). Species corresponding to binding of one thyroxine
molecule and one molecule of synthetic ligand labeled in red.
and each synthetic ligand. This experiment relies on binding. To investigate the possibility of different modes
of binding, the natural ligand thyroxine, with a well-sufficient differences in the molecular weights of the
ligand and thyroxine to distinguish the complexes established negatively cooperative binding mechanism
[13], was added in a stepwise fashion to a solution offormed in the resulting mass spectra (Figure 6). In the
presence of thyroxine and ligand 3, peaks correspond- wild-type TTR. The resulting mass spectra show that in
stoichiometric concentrations (2:1 thyroxine:TTR), theing in mass to wild-type TTR:31 and wild-type TTR:32
were observed with no evidence for binding of the natu- dominant series observed is that of TTR with only one
ligand associated, while a substantial level of apo TTRral ligand. For solutions containing equimolar ligand 1
with thyroxine, peaks corresponding to both wild-type remains (Figure 7). In excess ligand (3:1), a small signal
is evident corresponding to TTR:thyroxine2. As the con-TTR:1 and wild-type TTR:thyroxine were observed.
Identical experiments carried out in the presence of li- centration of thyroxine is increased, the peak assigned
to T2 is now pronounced, but only in vast excess (5:1)gand 2 showed a similar profile of peaks. Other synthetic
ligands examined in this way were found not to compete is formation of the fully saturated complex observed.
Using identical experimental conditions, the titration ofwith thyroxine since wild-type TTR:thyroxine was identi-
fied as the major product in each case. Similar experi- ligands 1 and 10 were examined in a similar manner.
The results of these titrations enable the proportion ofments carried out with the variant L55P demonstrated
that ligands 1, 2 and 3 had identical properties to those free tetramer as well as protein containing one and two
ligands to be measured as a function of inhibitor concen-observed for wild-type TTR when analyzed in competi-
tion with thyroxine. Interestingly, for both wild-type and tration (Figure 8). Close examination of the proportion of
each complex with one ligand reveals that for thyroxine,variant TTR, ligands 1 and 2 gave rise to a series of peaks
corresponding in mass to the binding of one molecule of ligand 1, and ligand 10, the populations are 0.75, 0.5,
and 0.3 respectively at a ligand concentration of 10 M.thyroxine and one molecule of an N-phenyl phenoxazine
derivative. This species demonstrates the existence of In order to explain these apparent differences in inten-
sity of ligand-bound species, we employed a KNF coop-TTR tetramers with one molecule of thyroxine and one
synthetic ligand and supports our hypothesis that these erative model ([27] see Experimental Procedures for de-
tails). Figure 8 shows the effect of the alteration ofsynthetic ligands are similar to thyroxine in their affinity
for binding to TTR. conformation of adjacent subunits on binding using this
model. At the Michealis-Menton limit, where KAB KBB
1, this is indicative of noncooperative binding. In theCooperativity of Ligand Binding
Dissociation of TTR complexes with ligand 10 (Figure case where the interaction between AB dimer conforma-
tion is disfavored and the BB conformation is favored,2) show that both molecules are lost simultaneously,
raising the possibility of a more cooperative mode of this gives rise to positive cooperative binding and very
Structure
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experimental data were obtained. The pattern of the
three peaks corresponding to apo TTR and binding of
one and two ligands were compared. For thyroxine the
major species at this ligand concentration is the com-
plex with one ligand. For ligand 1, all three species are
represented with binding of one ligand as the most
highly populated species. By contrast, for ligand 10, the
peak corresponding in mass to the binding of one ligand
was consistently lower than both apo and wild-type:102.
A similar pattern of peaks was observed when ligand
10 was examined with the V30M TTR, suggesting a more
cooperative mode of binding is also operative in this
case, although when examined with L55P, this effect
was less marked. All other ligands examined in this study
were found to bind with negative cooperativity. From
these MS results we can therefore conclude that while
the majority of ligands studied exhibit negative coopera-
tivity in binding to wild-type and variant TTR, some dis-
played more positive and noncooperative modes of
binding.
Formation of the TTR:Ligand:RBP:Retinol
Complex
During retinol transport, each RBP:retinol complex
makes contact with three TTR monomers (Figure 9), oneFigure 7. Titration of Thyroxine into Wild-Type TTR
in the upper and two in the lower TTR dimer [28]. ToThyroxine was added from stoichiometric concentrations up to 5:1
determine the effects of ligand binding to TTR on theligand:TTR. As the concentration was increased, binding in one site
RBP binding sites, we prepared holo TTR with thyroxinewas observed initially (gray) while with excess ligand, both sites
were occupied (black). and examined its interaction with the RBP:retinol com-
plex. From the mass spectra recorded for this complex
we determined that the major component had a molecu-
lar weight of 100,120 12 Da. This corresponds closelylittle of the species with one ligand bound is predicted.
When the magnitude of the constants is reversed from to that for a noncovalent complex consisting of four
subunits of transthyretin, two thyroxine molecules andthe positive cooperative case, negative cooperativity
occurs: the complex with one ligand is significantly pop- two complexes of RBP:retinol (100,084 Da), suggesting
that binding of the natural ligand to TTR does not perturbulated with respect to the apo tetramer and the complex
with two ligands. Only in the presence of excess ligand the RBP binding sites. To establish that binding of syn-
thetic ligands was indistinguishable from that of thyrox-concentrations are significant amounts of fully ligated
complex observed. Comparison of these theoretical ine, the 16 potential inhibitors were examined under
identical conditions and TTR:RBP complex formationcurves with those determined experimentally demon-
strates that for ligand 1, occupation of the second site was observed in each case. Figure 9 shows the mass
spectrum of TTR in the presence of RBP:retinol and(red) does not occur until after the complex containing
one ligand is populated up to a value of 0.5, as seen in ligand 2. The measured molecular weight of the major
series is consistent with that calculated for a ten-compo-the case of the noncooperative binding model, after
which saturation follows rapidly. This is in accord with nent complex with two synthetic ligands (2), indicating
that this ligand does not perturb the interactions of thisprevious data recorded for this class of molecule [13].
A similar trend is also observed for thyroxine, although system. Interestingly, not all of the TTR fully associated
with the RBP:retinol. Even in the presence of excessin this case occupation of the second ligand binding site
is impeded until the population containing one ligand is RBP:retinol, small proportions of holo TTR and holo TTR
with one RBP:retinol were observed. This is consistenthigher (0.75), indicative of a more negatively cooperative
binding mode than that observed for ligand 1 (Figure 8). with the M dissociation constants for these complexes
(typically 1.1  107 to 1.5  107M) [29] and was ob-By contrast, occupation of the first and second binding
site by ligand 10 occurs simultaneously, indicating that served irrespective of the presence of natural or syn-
thetic ligand. An additional series of peaks at low inten-10 binds to the protein in a positively cooperative fash-
ion, as binding of one site is statistically more likely than sity is also present (C2) and corresponds to the
association of two additional RBP:retinol complexes tobinding of two sites in the absence of cooperativity.
Individual peaks within the mass spectra were com- give the overall stoichiometry holoTTR(holoRBP)4. This
was not unexpected, as complexes with this stoichiome-pared with peaks generated theoretically using values
for the population of each state from the model. The try have been observed in other studies [30]. The low
population of this species suggests, however, that it isspectra were recorded with wild-type TTR and ligand
at 2.0 M equivalents for thyroxine, ligand 1, and ligand not favored under these conditions, the major species
being the ten-component holoTTR(holoRBP)2 complex.10. Excellent agreement between the simulations and
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Figure 8. Correlation between Theoretical
and Experimental Ligand Binding Data
(A) Binding curves calculated from mass
spectrometry data showing the population of
each of the liganded states as a function of
free ligand concentration. Green  apo TTR,
black one ligand bound (half height), red 
two ligands bound.
(B) Theoretical binding curves for a two-state
KNF model exhibiting (i) noncooperative be-
havior (KAB  KBB  1), (ii) positively coopera-
tive (KAB  0.1, KBB  10), and (iii) negatively
cooperative behavior (KAB  10, KBB  0.1).
Red two ligands bound, blue total ligand-
bound population, black one ligand bound,
mauve  noncooperative binding, green 
apo TTR.
(C) Individual charge states from the mass
spectra for (i) ligand 1, (ii) ligand 10, and (iii)
thyroxine with wild-type TTR (black). The li-
ganded states are marked in each case. The-
oretical mass spectra generated from the
binding curves in (B) are shown in blue (indi-
vidual) and red (combined).
It is important to note that in the population
graphs (A) and (B), T and T2 can vary between
0 and 2 ligands bound, whereas state 2 (T1)
can only vary between 0 and 1. For example,
in (8B) (left panel), at a free ligand concentra-
tion of 1 M, the three states have equal
amounts of each species. Consequently, T1
is 50% saturated (as it can vary between 0
and 1), whereas T and T2 are only 25% satu-
rated (as they can vary between 0 and 2).
This corresponds to a 1:2:1 ratio, the situation
seen experimentally in (8C) (left panel).
The multitude of noncovalent interactions involved in ciate more readily (data not shown), a feature also ob-
served for TTR without RBP:retinol. These observationsthe formation of these holoTTR(holoRBP)2 complexes
is reflected in the increased peak widths in the mass not only demonstrate the increased stability of the holo
TTR in the TTR:RBP complex, as in the tetramer, butspectrum. This is presumably as a result of additional
solvent molecules that are trapped during desolvation also that the TTR:RBP interactions are not impaired by
inhibitor molecule binding to TTR.of the complex or alternatively have a structural role
in the maintenance of the complex. Because of these To determine the effects of the amyloidogenic muta-
tions on the ability to form the TTR:RBP:retinol complex,effects, it was not possible to resolve species corre-
sponding to the binding of individual small molecule we examined both TTR variants in the presence of syn-
thetic ligands and RBP:retinol. The mass spectra con-ligands in the multiprotein complex. However, as desol-
vation energy is increased, the peaks become consider- firmed the presence of both holoV30M-TTR(holoRBP)2
and holoL55P-TTR(holoRBP)2. To investigate the bind-ably sharper, and a proportion of the ligands dissociate
(Figure 9). This gives rise to additional peaks corre- ing affinity of variant TTR for RBP:retinol we examined
wild-type and variant apo TTR in substoichiometric con-sponding to complexes containing none, one, and two
ligands, confirming the presence of ligand molecules in centrations of RBP:retinol solution (2:1 TTR:RBP). Com-
plexes corresponding to apo TTR and TTR with one andthe complex. Figure 10 shows a series of spectra re-
corded for the dissociation of the wild-type TTR:thyro- two complexes of RBP:retinol were observed in similar
proportions for wild-type and variant TTR, indicatingxine:RBP:retinol complex. Close examination of the mass
spectra reveals the relative ease of dissociation of the that these mutations do not affect the affinity of TTR for
RBP:retinol.various complexes. The major species, corresponding to
holoTTR(holoRBP)2 (C), remains intact throughout this
process. By contrast, loss of ligand occurs at much Implications for TTR Binding Sites
From the X-ray analysis of wild-type TTR:52, four bindinglower dissociation energy for holoTTR:holoRBP. For
holo TTR, ligand dissociation is evident even under the modes were identified, all of which demonstrated that
the carboxylic acid groups form H bonds with Lys15lowest desolvation energies. In the absence of the small
molecule inhibitors, the complexes were found to disso- residues in the outer binding cavity, while the CF3 groups
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Figure 9. Formation of the Ten-Component Complex
(A) The major series, C, indicates the formation of a 100 KDa complex comprising four TTR monomers, two ligands, and two RBP:retinol
complexes. C2 corresponds to a complex of C with two additional RBP:retinol complexes. Rn  n complexes of RBP:retinol. T  TTR tetramer,
T1  tetramer with one ligand, and T2  tetramer with two ligands. Charge states are indicated in parenthesis. Inset, proposed structure of
C with TTR subunits (blue), ligand 2 (green), RBP (red), and retinol (yellow). Boxed inset, interface of TTR, magnified to show the proposed
structure with RBP loops (orange and gray), which interact with three subunits of TTR. (Modified from PDB code 1QAB and 1DVY, Swiss-
PDB viewer 3.6b3. Rasterized with POV-Ray 3.1g).
(B) Dissociation of the multiprotein complex reveals multiple peaks assigned to individual ligand molecules.
occupy the innermost halogen binding pockets and the for the turbidity assays, these effects are likely to be
more pronounced than for the MS measurements wherephenyl rings provide van der Waals contacts [31]. From
the results obtained here, the absence of binding for a 3-fold excess of ligand was employed. Support for
this proposal comes from our observation that ligand 3ligands 17 and 18 can therefore be rationalized, since
neither contains a phenolic or carboxylic side chain competes most effectively with thyroxine for binding
sites in TTR. Although at this stage, it is not clear whichavailable for interactions with Lys15 (Figure 1). Ligands
15 and 16 have carboxylic acid side chains and were technique will provide the most accurate evaluation of
the effects of ligand binding on tetramer stability; thefound to bind but not to have any significant stabilizing
effect on the tetramer, suggesting that they are unable to apparent discrepancy between the MS and turbidity
measurements could be explained by the sensitivity ofeffect the interactions within the halogen binding pocket
that contribute to the additional stability of holoTTR. the turbidity assay to ligand binding affinities. For the MS
measurements, this effect is diminished by the higherOf the 18 ligands investigated in this study, the three
N-phenyl phenoxazine derivatives were found to be the concentration of ligand and the fact that the stability of
the tetramer complex at the molecular level providesmost effective in both binding to and stabilizing the
TTR tetramer. This finding is in accord with results from the rank order.
Examination of the polar surface area of the ligandsturbidity assays measurements [13]. Interestingly, some
differences in the detailed rank order of the ligands pro- (Figure 3) shows that the tightest binding ligands (1, 2,
and 3) have the highest values. This correlation, how-posed by the two techniques were observed. From tur-
bidity assays meta-substituents (structures 2 and 3) ever, does not hold for all ligands used in this study.
For example, ligand 15, which binds only weakly to thewere found to inhibit fibril formation more effectively
than para-substituted ligand 1, giving an overall rank tetramer, has the fourth highest value, while 4 has one
of the lowest values for polar surface area and yet isorder of 2  3  1. From the MS measurements, the
rank order for phenoxazine derivatives stabilizing the ranked fourth in our study. These results clearly show
that it is not simply polar surface area that dictates thetetramer was found to be 1 2 3. A possible explana-
tion for these differences is that burial of the hydropho- stability of the ligand-bound complex, but rather, the
spatial relationship between the structural features ofbic substituents of ligands 2 and 3 (trifluormethyl and
t-butyl, respectively) within the hydrophobic TTR bind- the ligand and the complementary functionalities within
the binding site.ing channel is energetically favorable. By contrast, burial
within the channel of the polar carboxylate substituent Close examination of the cooperativity of ligand bind-
ing demonstrates the existence of both positive andof ligand 1, hydrated in bulk solvent, is less energetically
favored. This would have the effect of increasing the noncooperative mechanisms in addition to the well-
established negative cooperativity for thyroxine binding.affinity of ligands 2 and 3 for TTR over 1. Since substoi-
chiometric and equimolar quantities of ligand were used These results are interesting in the light of X-ray analysis
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16) associate equally with both wild-type and variant
TTR. This suggests that subtle differences are operative
in the variant proteins that prevent ligand binding of
the flufenamic acid derivatives but allow association of
ligands 8 and 16 with variant TTR. These observations
suggest that small structural perturbations restrict the
binding channel for the nonplanar flufenamic acid deriva-
tives but not for the planar structures such as 8 and 16.
Given the fact that crystal structures of TTR have
shown high b factors for residues in the FG loop [6],
one of the regions involved in complexation with RBP
[33] and proposed as a source of the amyloidogenicity
in L55P TTR [34], it is conceivable that interactions with
RBP would be compromised in the TTR variants. In this
investigation, we demonstrate that the stability of the
two variant TTR RBP complexes are comparable to those
observed for the wild-type protein. In addition the ho-
loTTR:holoRBP complex was shown to be more stable
than the corresponding holo TTR complexes. This ob-
servation suggests that there is an increased strength of
subunit interactions in the holoTTR:holoRBP complex.
Biological Implications
Transthyretin is one of 20 or so human proteins linkedFigure 10. Stack Plot of Spectra Recorded under Increasing Desol-
vation Energy Conditions for the Thyroxine-Bound TTR:RBP with abnormal association that yields amyloid fibrils or
Complex plaques. The mechanism by which this occurs is not
As the desolvation energy is increased from 80 V to 200 V, dissocia- fully understood, but in vitro studies have shown that
tion of the complex demonstrates clearly the loss of ligands from stabilizing the protein in its native conformation reduces
TTR and the loss of RBP, prior to loss of ligand, from TTR:RBP significantly the yield of amyloid fibrils [10]. This has led
complexes. The components of each series are labelled as for Figure
to the proposal that small molecules that bind to and9. The region of the spectra from 5100–5700 m/z has been omitted
stabilize the native tetrameric structure are potentialfor clarity since it contains extensive overlap of the charge states
inhibitors of transthyretin amyloidosis. Research is un-for this multicomponent complex.
derway to develop small molecule treatments for such
disorders, including Alzheimer’s [35, 36], Creutzfeldt Ja-of ligand-bound TTR, which suggested that binding of
kob disease [37], and polyneuropathies [10, 13, 32].ligand 5 gives rise to a ligand-induced conformational
Using a novel mass spectrometry approach, we havechange in the protein [13, 32]. Recently however, based
examined wild-type transthyretin and two protein vari-on an examination of 23 TTR crystal structures, it was
ants associated with disease states, in the presencesuggested that there were no significant conformational
of a range of synthetic ligands. Of the 18 moleculeschanges upon the binding of ligand [6]. Given that the
examined, we have produced an order of efficacy formajority of the holo TTR crystal structures were obtained
stabilizing the transthyretin tetramer and have shownby soaking excess ligand into crystals of apo TTR, it is
that the most effective of these confer stability to thepossible that subtle changes may be prevented by the
tetramer comparable with nondisease-associated forms.constraints operative within the crystal lattice. The dif-
Overall, our results show that association of transthy-ferent cooperativities established in this study however
retin with these small molecule inhibitors results in aare only explained by ligand binding in one site inducing
substantial increase in the stability of the protein tetra-subtle changes in the other. For ligand 1, the binding
mer, potentially reducing their amyloidogenicity. Wemechanism was established as noncooperative and is
have demonstrated competitive binding in the presenceof interest since it differs from those of thyroxine and
of the natural ligand and established cooperativity ofother ligands examined in this study. The fact that ligand
binding. Importantly, we have also demonstrated that10 displayed a more positive cooperative binding mech-
association of ligand does not adversely affect the sec-anism than the other ligands may be due to an extended
ond biological function of this protein system. That thesehydrogen-bonded network, involving Ser117 and Thr119
synthetic ligands do not perturb binding of the second-deep within the binding pocket and the acidic phenolic
ary carrier protein, involved in transport of vitamin A, isgroups of this bis dichloro phenol ligand.
an important consideration in terms of a potential ther-Differences between the variants and wild-type pro-
apy for transthyretin amyloidoses.tein for binding synthetic ligands are difficult to rational-
ize if the overall structure of the ligand binding site re-
mains the same. Flufenamic acid derivatives 5 and 6 Conclusions
The results of this investigation demonstrate the insightsshow appreciable binding to wild-type TTR, but binding
was significantly reduced for the two variant proteins. that can be gained for potential transthyretin inhibitors
using this MS approach. The mutations, which renderSurprisingly, other more weakly binding ligands (8 and
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the protein highly unstable, did not prevent the ligand X  2KAB (KS Kt x)  2KBB (KS Kt x)
2
1  2KAB (KS Kt x)  KBB (KS Kt x)2
. (1)
from conferring additional stability to the structure. With-
out prior knowledge of the ligand structures, an order This model assumes that binding of the ligand (with respect to the
was produced that correlated well with the published free ligand concentration x, with intrinsic binding constant KS to a
protein in conformation A, leads to a conformational change todata for a subset of these ligands [13]. Using this novel
conformation B. The equilibrium between A and B is given by Kt approach, we were also able to assess the degree of
[B] / [A]. The constants KAB and KBB reflect the favorability, or other-cooperativity of ligand binding by generating directly
wise, of the protein being in an AB or a BB conformation. Thus if
the population of each of the bound and free states KAB  KBB, the resultant binding curve exhibits negative cooperativ-
as a function of ligand concentration. The procedure ity; conversely, if KAB 	 KBB, there is positive cooperativity. When
requires minimal sample since spectra are obtained us- KAB  KBB  1, then there is no cooperativity between the sites, and
the equation can be modeled by the Michealis-Menton-limiting caseing 1–2 l at a protein concentration of 20 M. This
[27]methodology yields definitive information about the abil-
ity of ligands not only to bind to tetrameric TTR, but
X 
2KS Kt x
1  KS Kt x
. (2)also to prevent the loss of protein interactions within
the complex. Moreover the demonstration that synthetic
The amount of each species as a function of free ligand concentra-ligand binding, like thyroxine, does not affect interac-
tion was calculated by
tions with a second carrier protein is significant in terms
of the physiological role of this protein in plasma.
[T0]  2/(1  2KAB (KS Kt x)  KBB (KS Kt x)2)
[T1]  {2KAB (KS Kt x)}/(1  2KAB (KS Kt x)  KBB (KS Kt x)2) 
.
Experimental Procedures
Proteins and Ligands
[T2]  {2KBB (KS Kt x)2}/(1  2KAB (KS Kt x)  KBB (KS Kt x)2) (3)
TTR and RBP were purified from E. coli expression systems de-
scribed previously [8, 38]. Protein was buffer exchanged using Micro Mass spectra for each of the cooperative cases were modeled using
Bio-spin 6 columns (Bio-Rad Laboratories, Hercules, CA) into 20 three gaussian distributions, calculated from Equation (1) at a con-
mM ammonium acetate, pH 4.4 or 7.0. Thyroxine, retinol, and buffer centration of 1  10 M for thyroxine and ligand 1 and 0.75  106
components were sourced from Sigma (Poole, Dorset, UK). Analysis M for ligand 10. The mean positions were set to the known m/z
was carried out in 2.5% DMSO. Ligands were synthesized as de- values of unliganded and liganded TTR. All binding curves and mass
scribed previously [12, 13], dissolved into DMSO, and added to TTR spectra were displayed using SigmaPlot 2000 (Jandel Scientific).
solution (20 M) with a 3-fold excess of ligand (unless otherwise Experimental mass spectra were fitted to three gaussian functions
stated). Protein concentration was determined by absorbance spec- using a user-defined nonlinear regression routine in SigmaPlot. An
troscopy [39]. Association of RBP with retinol greatly improved its arbitrary value of 1 106 M was adopted for the Kd of the ligands
complexation with TTR, and this practice was subsequently as values were not available for the solution conditions of our study.
adopted. All-trans retinol was added to RBP from a concentrated
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